225 related articles for article (PubMed ID: 33840206)
1. Lasmiditan for the acute treatment of migraine.
DeJulio PA; Perese JK; Schuster NM; Oswald JC
Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
3. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
[TBL] [Abstract][Full Text] [Related]
4. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
5. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
6. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
[TBL] [Abstract][Full Text] [Related]
7. Short-term efficacy and safety of lasmiditan, a novel 5-HT
Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
[TBL] [Abstract][Full Text] [Related]
8. Targeted 5-HT
Vila-Pueyo M
Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
[TBL] [Abstract][Full Text] [Related]
9. Lasmiditan for acute treatment of migraine.
Parikh S
Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
[TBL] [Abstract][Full Text] [Related]
10. The Effect and Safety of 5-HT
Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
[TBL] [Abstract][Full Text] [Related]
11. Lasmiditan: an additional therapeutic option for the acute treatment of migraine.
Martinelli D; Bitetto V; Tassorelli C
Expert Rev Neurother; 2021 May; 21(5):491-502. PubMed ID: 33866907
[No Abstract] [Full Text] [Related]
12. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
13. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
[No Abstract] [Full Text] [Related]
14. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
15. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC; Olesen J
J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
[TBL] [Abstract][Full Text] [Related]
16. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
[TBL] [Abstract][Full Text] [Related]
17. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
19. Lasmiditan: First Approval.
Lamb YN
Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
[TBL] [Abstract][Full Text] [Related]
20. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
